Optimizing Outcomes in Relapsed and Refractory Multiple Myeloma: Personalized Approaches and Adverse Event Management.
No abstract available
References:
M. V. Mateos, K. Weisel, V. De Stefano, et al., “LocoMMotion: A Prospective, Non‐Interventional, Multinational Study of Real‐Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma,” Leukemia 36, no. 5 (2022): 1371–1376, https://doi.org/10.1038/s41375‐022‐01531‐2.
P. Karschnia, J. T. Jordan, D. A. Forst, et al., “Clinical Presentation, Management, and Biomarkers of Neurotoxicity After Adoptive Immunotherapy With CAR T Cells,” Blood 133, no. 20 (2019): 2212–2221, https://doi.org/10.1182/blood‐2018‐12‐893396.
L. Neill, J. Rees, and C. Roddie, “Neurotoxicity‐CAR T‐Cell Therapy: What the Neurologist Needs to Know,” Practical Neurology 20, no. 4 (2020): 285–293, https://doi.org/10.1136/practneurol‐2020‐002550.
Drugs.com, “Belantamab Mafodotin Side Effects” (2023), https://www.drugs.com/sfx/belantamab‐mafodotin.html.
A. A. Argyriou, G. Iconomou, and H. P. Kalofonos, “Bortezomib‐Induced Peripheral Neuropathy in Multiple Myeloma: A Comprehensive Review of the Literature,” Blood 112, no. 5 (2009): 1593–1599, https://doi.org/10.1182/blood‐2008‐04‐149385.